Report Description Table of Contents Angiography Equipment Market Size, Share, Trends & Forecast, 2026–2032 Updated: August 29, 2026 | Strategic Market Research 2025 Market Size 2032 Forecast CAGR Forecast Period USD 12.65 Billion USD 18.77 Billion 5.8% 2026–2032 What Is the Angiography Equipment Market Size and How Is Image-Guided Vascular Care Evolving? The Global Angiography Equipment Market was valued at USD 12.65 billion in 2025 and is projected to reach USD 18.77 billion by 2032, expanding at a CAGR of 5.8% during 2026–2032, according to Strategic Market Research. Angiography equipment supports blood-vessel visualization and image-guided diagnosis or treatment across coronary, peripheral, neurovascular and visceral procedures. SMR defines this market to include capital angiography systems plus directly linked catheters, guidewires, balloon catheters, contrast media, vascular-closure products and procedure accessories. CTA and MRA revenues are counted only for angiographic applications, not total CT or MRI scanner sales. WHO estimated 19.8 million cardiovascular deaths in 2022 New technology in angiography equipment is increasingly focused on AI-enabled imaging, radiation dose reduction, and hybrid imaging suites. Systems from Shimadzu, Canon, and Siemens Healthineers use deep-learning image processing, automated motion correction, and procedural guidance to improve visualization and treatment accuracy. Advanced imaging algorithms can also reduce X-ray exposure while maintaining image quality. At the same time, Angio-CT and ultrasound–fluoroscopy fusion are enabling clinicians to combine anatomical imaging and real-time procedural guidance within a single interventional workflow. What Are the Key Report Takeaways for the Angiography Equipment Market? By Product Type: Angiography Systems lead with 38.0% or USD 4.81 billion in 2025. Catheters hold 15.0% or USD 1.90 billion; Contrast Media 14.0% or USD 1.77 billion; Guidewires 10.0% or USD 1.27 billion; Vascular Closure Devices 9.0% or USD 1.14 billion; Balloon Catheters 7.0% or USD 0.89 billion; and Accessories 7.0% or USD 0.89 billion. By Technology: X-Ray Angiography dominates with 64.0% or USD 8.10 billion. CTA represents 23.0% or USD 2.91 billion and has the fastest technology CAGR at 6.69%; MRA accounts for 13.0% or USD 1.64 billion. By Procedure: Coronary Angiography leads at 39.0% or USD 4.93 billion. Non-coronary Endovascular Angiography holds 23.0% or USD 2.91 billion, Peripheral 16.0% or USD 2.02 billion, Neuroangiography 15.0% or USD 1.90 billion, and Other Procedures 7.0% or USD 0.89 billion. Neuroangiography is fastest-growing at 6.51%. By End User: Hospitals account for 62.0% or USD 7.84 billion, Diagnostic Centers 19.0% or USD 2.40 billion, ASCs 13.0% or USD 1.64 billion, and Academic & Research Institutes 6.0% or USD 0.76 billion. ASCs grow fastest at 7.04%. By Application: Diagnostics represent 57.0% or USD 7.21 billion; Therapeutics hold 43.0% or USD 5.44 billion and grow faster at 6.36%. By Geography: North America leads with 39.0% or USD 4.93 billion, Europe 27.0% or USD 3.42 billion, Asia-Pacific 24.0% or USD 3.04 billion, Latin America 6.0% or USD 0.76 billion, and Middle East & Africa 4.0% or USD 0.51 billion. Asia-Pacific is fastest-growing at 7.02%. How Is Product Mix Shaping the Angiography Equipment Market? Angiography Systems accounted for 38.0%, representing USD 4.81 billion in 2025, and are projected to expand at a CAGR of 5.68%. They remain the central capital asset in cath labs. Competition now centers on cone-beam CT, 3D reconstruction, AI-assisted processing, automated positioning, procedure breadth and service uptime. Angiography Catheters held 15.0%, or USD 1.90 billion, and are forecast to grow at 6.28%. Revenue follows procedure volume. Catheter shape, coating, torque response and trackability affect vessel selection and contrast delivery, with Terumo OPTITORQUE and GLIDECATH illustrating coronary and peripheral portfolio breadth. Angiography Balloon Catheters represented 7.0%, or USD 0.89 billion, and are projected to grow at 5.48%. They are tied mainly to therapeutic angioplasty after a lesion is crossed with a guidewire, so utilization tracks PCI and peripheral intervention more closely than diagnostic angiography. Angiography Contrast Media accounted for 14.0%, or USD 1.77 billion, and are forecast to expand at 5.18%. Iodinated agents remain essential to X-ray angiography and CTA. FDA labeling for Bayer’s Ultravist includes coronary, cerebral, peripheral and visceral angiographic applications.[10] Vascular Closure Devices represented 9.0%, or USD 1.14 billion, and have the fastest product CAGR at 6.48%. Abbott Perclose ProStyle supports femoral access-site closure after catheter-based procedures, linking revenue to hemostasis and post-procedure workflow.[11] Angiography Guidewires accounted for 10.0%, or USD 1.27 billion, and are projected to expand at 6.08%. They provide the rail for diagnostic and therapeutic devices. Boston Scientific’s Thruway is indicated to facilitate catheter placement during peripheral intravascular procedures.[12] Accessories held 7.0%, or USD 0.89 billion, and are projected to grow at 5.58%. Introducer components, tubing, connectors and other sterile support products provide recurring procedure-linked revenue. How Are X-Ray Angiography, CTA and MRA Changing the Vascular Imaging Pathway? X-Ray Angiography represented 64.0%, or USD 8.10 billion, and is projected to expand at 5.39%. Real-time fluoroscopic guidance remains essential during catheter and device navigation, while cone-beam CT and 3D software extend the room into complex image-guided treatment. Magnetic Resonance Angiography accounted for 13.0%, or USD 1.64 billion, and is projected to grow at 6.19%. MRA provides non-invasive vascular imaging without ionizing radiation, but scanner access, acquisition time and limited real-time interventional use keep it complementary to cath-lab fluoroscopy. Computed Tomography Angiography held 23.0%, or USD 2.91 billion, and has the fastest technology CAGR at 6.69%. CTA can substitute for some diagnostic invasive studies while also selecting patients for intervention, making it both a competitive and feeder modality. Which Procedures Create the Largest Angiography Equipment Market Revenue Pools? Coronary Angiography accounted for 39.0%, or USD 4.93 billion, and is projected to expand at 5.41%. Coronary imaging remains embedded in ACS and PCI pathways, supporting recurring use of systems, catheters, guidewires, contrast and access products.[2][9] Non-coronary Endovascular Angiography represented 23.0%, or USD 2.91 billion, and is projected to grow at 6.31%. It covers other image-guided vascular procedures where angiography localizes lesions, guides devices and confirms treatment. Neuroangiography held 15.0%, or USD 1.90 billion, and has the fastest procedure CAGR at 6.51%. Stroke thrombectomy, aneurysm treatment and AVM intervention favor biplane imaging, 3D reconstruction and rapid workflow, supporting premium configurations. Peripheral Angiography accounted for 16.0%, or USD 2.02 billion, and is forecast to expand at 5.71%. Lower-extremity and other peripheral procedures create both imaging-system utilization and recurring catheter, guidewire and angioplasty-device consumption. Other Procedures represented 7.0%, or USD 0.89 billion, and are projected to grow at 4.91%. Renal, visceral and other specialized applications share installed angiography infrastructure but occur at lower aggregate volumes. How Are Care Settings Changing Angiography Equipment Purchasing? Hospitals accounted for 62.0%, or USD 7.84 billion, and are projected to expand at 5.54%. Emergency PCI, stroke intervention and complex procedures keep hospitals central. Indonesia’s Health Systems Strengthening project is deploying 419 catheterization laboratories and is expected to upgrade equipment across 560 hospitals by 2029.[13] Diagnostic Centers represented 19.0%, or USD 2.40 billion, and are projected to grow at 6.04%. Their role is concentrated in CTA and MRA, where outpatient vascular imaging diagnoses disease and refers higher-risk patients for invasive assessment. Ambulatory Surgical Centers held 13.0%, or USD 1.64 billion, and record the fastest end-user CAGR at 7.04%. ACC’s CV ASC Registry covers diagnostic catheterization and PCI in ASCs, OBLs and outpatient centers.[14] U.S. PCI sites without on-site cardiac surgery rose from 296 in 2009 to 715 in 2021, reaching 43% of PCI-capable sites.[15] Academic & Research Institutes represented 6.0%, or USD 0.76 billion, and are projected to grow at 4.84%. Their smaller revenue share reflects fewer sites, but they remain important for advanced imaging evaluation, training and new navigation workflows. How Are Diagnostic and Therapeutic Applications Shaping Angiography Equipment Revenue? Diagnostics accounted for 57.0%, or USD 7.21 billion, and are projected to expand at 5.36%. Catheter angiography, CTA and MRA serve broad coronary, cerebral, peripheral and visceral assessment pathways, keeping diagnostics the larger application pool. Therapeutics represented 43.0%, or USD 5.44 billion, and are projected to grow faster at 6.36%. PCI, peripheral intervention, thrombectomy and embolization turn the angiography room into a treatment platform and increase the value of advanced imaging, navigation software and recurring devices. Where Is Angiography Equipment Investment Expanding Fastest? North America accounted for 39.0%, or USD 4.93 billion, and is projected to expand at 5.22%. A large cath-lab base creates replacement and upgrade revenue, while 2025–2026 FDA clearances show an active refresh cycle.[4–8] Decentralization of PCI also broadens the addressable facility base.[15] Europe held 27.0%, or USD 3.42 billion, and is forecast to grow at 5.32%. Mature intervention networks emphasize replacement, software and higher-specification rooms. In the UK, intracoronary imaging was used in 32% of complex PCI cases in 2024/25, reinforcing integration of complementary imaging in difficult procedures.[16] Asia-Pacific represented 24.0%, or USD 3.04 billion, and records the fastest regional CAGR at 7.02%. Japan’s angiography activity shows mature infrastructure, while Indonesia adds greenfield expansion. Philips has agreements to deploy Azurion systems across all 38 Indonesian provinces with services and training.[17] Latin America accounted for 6.0%, or USD 0.76 billion, and is projected to expand at 6.12%. Growth is concentrated in tertiary and public cardiovascular centers. Brazil’s HC-UFTM inaugurated a new angiography/hemodynamics system in April 2025 to serve Uberaba and 26 surrounding municipalities.[18] Middle East & Africa represented 4.0%, or USD 0.51 billion, and are projected to grow at 6.42%. Specialized tertiary centers remain key purchasers. Saudi Arabia’s Ministry of Health reported advanced cardiac catheterization capacity across four major facilities during the 2026 Hajj season.[19] Which Companies Are Defining Competition in the Angiography Equipment Market? Competition in capital equipment centers on image quality, C-arm geometry, cone-beam CT, AI processing, procedure breadth, room access, workflow software and lifecycle service. Philips Philips competes through Azurion. Azurion R3.1 received FDA 510(k) clearance on October 24, 2025, while its Indonesian agreements demonstrate multi-year system, service and training partnerships.[4][17] Siemens Healthineers Siemens Healthineers expanded ARTIS in 2026, receiving FDA clearance for six interventional systems using the Optiq AI imaging chain. Siemens says Optiq AI applies deep-learning-based noise reduction across fluoroscopy, acquisition and DSA.[20] GE HealthCare GE HealthCare’s Allia Moveo received FDA clearance on December 9, 2025, and its first worldwide installation was announced in France in February 2026. The platform combines a cable-free C-arm, cone-beam CT and AI-powered guidance.[5][21] Canon Medical Canon Medical’s Alphenix V9.6 with aEvolve Imaging received FDA 510(k) clearance on March 10, 2026, supporting its position across cardiac, vascular and interventional radiology workflows.[6] United Imaging Healthcare United Imaging’s uAngio AVIVA CX received FDA 510(k) clearance on April 28, 2025, adding another full-system competitor to a market historically led by a small group of multinational imaging OEMs.[8] What Will Shape the Angiography Equipment Market Through 2032? The commercial opportunity differs by market maturity. Developed markets are likely to generate more revenue from replacements, premium configurations, software upgrades and service contracts, while health systems expanding referral infrastructure can create large greenfield installations. Indonesia’s 419-cath-lab program shows how national procurement can reshape an installed base.[13] Procedure mix will increasingly determine room value. Neurovascular intervention, complex PCI and embolization favor biplane imaging, 3D reconstruction, cone-beam CT and navigation, while CTA can reduce some purely diagnostic catheter angiography. Suppliers therefore need to position invasive systems around treatment-intensive procedures where real-time guidance cannot be replaced. The main constraints remain capital cost, room construction, trained staff, case-volume economics and service uptime. Through 2032, competitive advantage will come from combining broad procedure capability, recurring device pull-through, software and service attachment, high utilization and reliable support across the image-guided vascular-care pathway. Angiography Equipment Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 12.65 Billion Revenue Forecast in 2032 USD 18.77 Billion Overall Growth Rate CAGR of 5.8% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Billion, CAGR (2026 – 2032) Segmentation By Product Type, By Technology, By Procedure, By End User, By Application, By Geography By Product Type Angiography Systems, Angiography Catheters, Angiography Contrast Media, Angiography Guidewires, Vascular Closure Devices, Angiography Balloon Catheters, Accessories By Technology X-Ray Angiography, Computed Tomography Angiography, Magnetic Resonance Angiography By Procedure Coronary Angiography, Non-coronary Endovascular Angiography, Peripheral Angiography, Neuroangiography, Other Procedures By End User Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, Academic & Research Institutes By Application Diagnostics, Therapeutics By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, Japan, China, India, South Korea, Australia, Indonesia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Replacement and upgrade of cath-lab infrastructure, growth in neurovascular and peripheral interventions, expansion of catheterization laboratories, adoption of AI-enabled imaging, demand for lower radiation exposure, outpatient PCI growth, and recurring procedure-linked device consumption Customization Option Available upon request Frequently Asked Question About This Report Who are the Major Players in the Angiography Equipment Market? Major players include GE Healthcare, Siemens Healthineers, Philips Healthcare, Canon Medical Systems, and Boston Scientific Corporation. Which region held the largest Angiography Equipment Market share? North America held the largest market share, driven by advanced healthcare infrastructure and high adoption rates of cutting-edge technologies. Which Application/Type had the largest Angiography Equipment Market share? Coronary angiography is the largest application segment, owing to its critical role in diagnosing and treating cardiovascular diseases. How big is the Angiography Equipment Market? The global angiography equipment market was valued at approximately $13.4 billion in 2023 and is projected to grow at a CAGR of 6.3% from 2024 to 2030. What are the key factors driving the growth of the Angiography Equipment Market? Key drivers include the rising prevalence of cardiovascular diseases, advancements in imaging technologies, and increasing demand for minimally invasive procedures. .Q1. What is driving the shift toward advanced solutions in the industry? A1. Hospitals increasingly need angiography platforms that support both diagnosis and treatment within the same procedure. AI-assisted imaging, cone-beam CT, 3D reconstruction, lower radiation exposure, and automated procedural guidance are therefore becoming more important purchasing criteria. Q2. What new developments are expected to influence the market? A2. Hybrid Angio-CT suites, ultrasound–fluoroscopy fusion, deep-learning image processing, and automated motion correction are expected to reshape interventional workflows. These technologies can improve vessel visualization while helping clinicians manage increasingly complex coronary, peripheral, and neurovascular procedures. Q3. What are the major opportunities available in the industry? A3. Neuroangiography, therapeutic interventions, and ambulatory cardiovascular procedures offer some of the strongest opportunities. National cath-lab expansion programs in emerging markets also create significant potential for new system installations, service contracts, and recurring consumable sales. Q4. What factors are supporting growth across major regions in the market? A4. North America is supported by cath-lab replacement cycles and outpatient intervention, while Europe is investing in advanced imaging for complex procedures. Asia-Pacific is growing faster through new hospital infrastructure, national cardiovascular programs, and large-scale cath-lab deployment. Q5. How is competition evolving among key players in the industry? A5. Competition is shifting from basic image quality toward AI processing, workflow automation, cone-beam CT, room flexibility, and lifecycle service. Philips, Siemens Healthineers, GE HealthCare, Canon Medical, and United Imaging are introducing newer platforms to strengthen their positions in complex interventional care. Q6. What factors could limit future market growth? A6. High equipment costs, room-construction requirements, trained-staff shortages, and service dependence can slow adoption. CTA and MRA can also replace some purely diagnostic invasive procedures, increasing pressure on angiography systems to demonstrate greater value in treatment-intensive applications. Sources: [1] WHO — Cardiovascular diseases, 31 July 2025 [2] AIHW — Hospital care and procedures, 2023–24 [3] Japan MHLW — Survey of Medical Institutions 2023 [4] FDA — Azurion R3.1, K251827 [5] FDA — Allia Moveo, K251199 [6] FDA — Alphenix V9.6, K253584 [7] FDA — ARTIS genio floor / icono.explore floor, K253752 [8] FDA — uAngio AVIVA CX, K243376 [9] AHA/ACC — 2025 Acute Coronary Syndromes Guideline [10] FDA — Ultravist prescribing information [11] FDA — Perclose ProStyle physician labeling [12] Boston Scientific — Thruway Guidewire indications [13] World Bank — Indonesia Health Systems Strengthening, 2026 [14] ACC — CV ASC Registry Suite [15] ACC/NCDR — PCI without on-site cardiac surgery, 2026 [16] NICOR — National Audit of PCI 2024/25 [17] Philips — Indonesia nationwide Azurion deployment, 2025 [18] Brazil HU Brasil — HC-UFTM new hemodynamics equipment, 2025 [19] Saudi Ministry of Health — Specialized cardiac care during Hajj 1447H [20] Siemens Healthineers — Six new ARTIS systems with Optiq AI, 2026 [21] GE HealthCare — Allia Moveo clearance and first installation, 2026 Table of Contents - Global Angiography Equipment Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product Type, Technology, Procedure, End User, Application, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product Type, Technology, Procedure, End User, Application, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product Type, Technology, Procedure, End User, and Application Investment Opportunities in the Angiography Equipment Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Advanced Angiography Systems, AI-Enabled Imaging, Neurovascular Intervention, Peripheral Intervention, Outpatient Cardiovascular Care, and Image-Guided Therapeutics Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Angiography Equipment in Image-Guided Vascular Diagnosis and Interventional Care Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory, Reimbursement, and Capital Investment Factors Role of AI-Enabled Imaging, Cone-Beam CT, Three-Dimensional Reconstruction, and Hybrid Imaging in Market Expansion Radiation Dose Reduction, Workflow Optimization, Image Quality, and Procedure Efficiency Trends in Angiography Global Angiography Equipment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type: Angiography Systems Angiography Catheters Angiography Contrast Media Angiography Guidewires Vascular Closure Devices Angiography Balloon Catheters Accessories Market Analysis by Technology: X-Ray Angiography Computed Tomography Angiography Magnetic Resonance Angiography Market Analysis by Procedure: Coronary Angiography Non-coronary Endovascular Angiography Peripheral Angiography Neuroangiography Other Procedures Market Analysis by End User: Hospitals Diagnostic Centers Ambulatory Surgical Centers Academic & Research Institutes Market Analysis by Application: Diagnostics Therapeutics Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Angiography Equipment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Technology, Procedure, End User, and Application Country-Level Breakdown: United States Canada Mexico Europe Angiography Equipment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Technology, Procedure, End User, and Application Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Angiography Equipment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Technology, Procedure, End User, and Application Country-Level Breakdown: China India Japan South Korea Australia Indonesia Rest of Asia-Pacific Latin America Angiography Equipment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Technology, Procedure, End User, and Application Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Angiography Equipment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Technology, Procedure, End User, and Application Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Philips Siemens Healthineers GE HealthCare Canon Medical Systems Corporation United Imaging Healthcare Shimadzu Corporation Terumo Corporation Abbott Laboratories Boston Scientific Corporation Competitive Landscape and Strategic Insights Benchmarking Based on Image Quality, C-Arm Geometry, Cone-Beam CT Capability, AI Processing, Procedure Breadth, Workflow Integration, Service Network, and Regional Presence Supplier Qualification, Regulatory Approval, and Service Capability Analysis Advanced Angiography System Positioning Neurovascular, Coronary, and Peripheral Intervention Competitiveness AI-Enabled Imaging, Three-Dimensional Reconstruction, and Dose Reduction Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Product Type, Technology, Procedure, End User, Application, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Regulatory Compliance and Procurement Risk Analysis Technology Adoption Trends Across X-Ray Angiography, Computed Tomography Angiography, and Magnetic Resonance Angiography List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Product Type, Technology, Procedure, End User, and Application (2025 vs. 2032) Global Angiography Equipment Ecosystem and Value Chain Analysis